02 March, 2026
March marks Brain Tumour Awareness Month, a time to increase understanding of one of the most complex and challenging forms of cancer. While public awareness often focuses on symptoms, imaging, surgery, and treatment pathways, the contribution of the clinical laboratory is equally vital. High-quality laboratory data supports accurate diagnosis, informs prognosis, and helps clinicians monitor patients throughout their treatment journey.
Among the many tools available to healthcare professionals, tumour marker testing plays a valuable – and evolving – role in the management of brain tumours.
Understanding Brain Tumours
Brain tumours can be either primary tumours, which originate in the brain or central nervous system, or secondary (metastatic) tumours, which spread from cancers elsewhere in the body. Because of their location and biological diversity, diagnosis and monitoring often require a combination of imaging, histopathology, and biochemical testing.
Although there is no single universal serum tumour marker for all primary brain tumours, specific markers are highly relevant in certain tumour types, particularly:
- Germ cell tumours of the central nervous system – associated with AFP and β-hCG
- Metastatic brain disease – where markers such as CEA, CA 15-3, CA 19-9, or PSA may support identification of the primary malignancy and disease monitoring
In these clinical scenarios, tumour marker measurement provides important complementary information that helps guide patient management.
Supporting Diagnosis and Tumour Classification
For some intracranial germ cell tumours, tumour markers such as AFP and β-hCG can:
- Help differentiate tumour subtypes
- Reduce the need for invasive diagnostic procedures in certain cases
- Support faster clinical decision-making
Accurate measurement is critical, as tumour classification directly influences treatment strategy and prognosis.
Informing Prognosis and Treatment Planning
Tumour marker concentrations can reflect tumour burden and biological behaviour. In patients with marker-secreting tumours, baseline levels taken at diagnosis provide an important reference point for:
- Risk stratification
- Treatment planning
- Evaluating therapeutic response
A significant reduction in marker levels during treatment is often associated with a favourable response, while persistently elevated or rising values may indicate residual disease or treatment resistance.
Monitoring Treatment Response and Detecting Recurrence
One of the most important applications of tumour markers in brain tumour pathways is longitudinal monitoring.
Serial measurement allows clinicians to:
- Assess the effectiveness of surgery, chemotherapy, or radiotherapy
- Detect early signs of relapse
- Support timely clinical intervention
Because patient management depends on changes in marker concentration over time, analytical consistency is essential. Even small variations in reported values can affect clinical interpretation.
Why Result Accuracy Is Critical in Brain Tumour Pathways
Brain tumour patients often undergo long and complex treatment journeys, with tumour marker results compared across multiple time points.
Inconsistent or unreliable results can lead to:
- Misinterpretation of treatment response
- Unnecessary imaging or invasive procedures
- Delays in adjusting therapy
This makes robust assay performance and standardisation a fundamental requirement for laboratories supporting neuro-oncology services.
The Role of Quality Control and Calibration in Reliable Tumour Marker Testing
To deliver results clinicians can trust, laboratories must ensure that tumour marker assays consistently perform to the highest analytical standards.
High-quality controls and calibrators help to:
- Verify assay accuracy and precision
- Maintain lot-to-lot consistency
- Ensure comparability of results over time
- Support traceability and standardisation
For patients with brain tumours who require long-term monitoring, this level of analytical confidence is essential for detecting clinically meaningful change.
By implementing well-characterised materials designed specifically for tumour marker testing, laboratories can provide dependable data that directly supports patient care.
➡️ Discover how our tumour marker controls and calibrators help ensure reliable, reproducible performance across a wide range of analysers: https://www.fortressdiagnostics.com/products/controls-calibrators/tumour-marker
